Evidence map›Paper›PMID 42126143›Full record

ArticleHaemophilia : the official journal of the World Federation of Hemophilia2026

Seventh Åland Island Meeting on von Willebrand Disease.

Riitta Lassila, Ruben Bierings, Nathan T Connell, Fernando F Corrales-Medina, Augusto B Federici, Veronica H Flood, Floor Heubel-Moenen, Jill M Johnsen, Geoffrey Kuppens, Davide Matino and 8 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Haemophilia : the official journal of the World Federation of Hemophilia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Riitta LassilaCoagulation Disorders Unit, Department of Haematology, and the Research Program of Systems Oncology, HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Ruben BieringsErasmus MC, Rotterdam, Netherlands.
Nathan T ConnellBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Fernando F Corrales-MedinaDivision of Pediatric Hematology-Oncology, University of Miami-Miller School of Medicine and University of Miami-Hemophilia and Thrombosis Comprehensive Treatment Center, Miami, Florida, USA.
Augusto B FedericiL. Sacco University Hospital, University of Milan, Milan, Italy.
Veronica H FloodMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Floor Heubel-MoenenMaastricht University Medical Center and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Maastricht, the Netherlands.
Jill M JohnsenUniversity of Washington, Seattle, Washington, USA.
Geoffrey KuppensCentre for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Centre Utrecht, Utrecht, the Netherlands.
Davide MatinoFaculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Carolyn MillarCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Ingmar SchoenSchool of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Anish ShardaYale University School of Medicine, New Haven, Connecticut, USA.
Robert F SidonioDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Alok SrivastavaSt. Johns Research Institute & Department of Clinical Haematology, St. John's Medical College Hospital, St. John's National Academy of Health Sciences, Bengaluru, India.
Timea SzantoCoagulation Disorders Unit, Division of Haematology, HUCH Comprehensive Cancer Centre, Helsinki, Finland.
Angela C WeyandUniversity of Michigan Hemophilia and Coagulation Disorders, Ann Arbor, Michigan, USA.
Erik BerntorpMalmö Centre for Thrombosis and Haemostasis, Lund University, Lund, Sweden.

Funding

Octapharma AG
6 · The paper itself

Abstract

introductionThe seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024.

aimThe meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD. RESULTS AND DISCUSSION: The topics covered both clinical aspects of management and biochemical and laboratory insights into the disease. The clinical topics discussed included epidemiology of VWD, the diagnostic landscape and treatment strategies. Special attention was paid to the challenges of VWD in women and to the definition of disease severity, both key areas of ongoing clinical debate. Emerging research in bleeding disorders was also highlighted. Much has been achieved in the diagnosis and treatment of VWD, and the outlook is positive for people with VWD, who can expect continued improvements in their care in the coming years. To ensure optimal translation of increased understanding to improved care of people with VWD, a multidisciplinary approach with biochemists, geneticists and cell biologists partnering with clinicians and industry is needed.

Indexed as

von Willebrand DiseasesFemaleFinlandHumansvon Willebrand Factorvon Willebrand Factordiagnostic techniques and proceduresprophylaxisvon Willebrand diseasevon Willebrand factorwomen's health

Identifiers

PMID42126143
PMCPMC13586422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.